Hysterectomy – a life-saving as well as a life-enhancing operation?

Menopause International

Volumn 15, Issue 1, 2009, Pages 2-3

  Studd, John ^a  

^a London PMS and Menopause Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG CONTRAINDICATION; ECONOMICS; EDITORIAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; RISK; CANCER INCIDENCE; ENDOMETRIUM CANCER; MORTALITY; OVARIECTOMY;

CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYSTERECTOMY; RISK;

ESTRADIOL; TESTOSTERONE;

EID: 65549142287     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2009.009009     Document Type: Editorial

References (6)

1. Shuster LT, Gostout BS, Brossardt BR, Rocca W. A prophylactic oophorectomy in premenopausal women and long term health. Menopause Int 2008; 14: 111–16
2. Gath D, Rose N, Bond A, Garrod A, Hodges S. Hysterectomy and psychiatric disorder. Psychol Med 1995; 25: 277–83
3. Khastgir G, Studd J. Patient's outlook experience and satisfaction with hysterectomy bilateral oophorectomy and subsequent hormone replacement therapy. Am J Obstet Gynecol 2000; 183: 1427–33
4. Parker WH, Broder MS, Liu Z, Shoupe D, Farquar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005; 106: 219–26
5. Anderson GL, Limacher M, Assaf AR,, et al. Effects of conjugated equine estrogens on patients with hysterectomy. The WHI randomized controlled trial. JAMA 2004; 14: 1701–12
6. Studd J. Prophylactic oophorectomy. Br J Obstet Gynaecol 1989; 96: 506–509